Novartis strikes another billion-dollar oncology deal with acquisition of an early PI3Kalpha oral therapy
At the centre of the deal is SNV4818, currently being evaluated in a Phase 1/2 study. The oral…
Rio Tinto and Glencore release statements regarding possible merger
Save to read list
…
Roche’s Giredestrant Misses Key Goal in First-Line Breast Cancer Study
Roche RHHBY announced results from a late-stage study evaluating its investigational candidate, giredestrant, in combination with palbociclib for patients…
Roche’s Giredestrant Misses Key Goal in First-Line Breast Cancer Study
Roche RHHBY announced results from a late-stage study evaluating its investigational candidate, giredestrant, in combination with palbociclib for patients…
Roche Shares Fall After Breast-Cancer Treatment Misses Goal in Late-Stage Study
Roche said the company sees a path forward for combining giredestrant with another drug. – Sedat Suna/Getty Images…
Health Canada Approves Roche’s Columvi® (glofitamab) as the First Bispecific Antibody in Canada for Relapsed or Refractory Diffuse Large B-Cell Lymphoma after Initial Therapy
DLBCL is an aggressive cancer with a high risk of progression meaning urgent and effective treatments are needed…
FDA Accepts Roche’s NDA Seeking Approval for Breast Cancer Drug
Roche RHHBY announced that the FDA has accepted its new drug application (NDA) for giredestrant, an investigational oral therapy,…
Roche’s Columvi combination shows sustained survival benefit at three-year follow up of pivotal phase III STARGLO study
F. Hoffmann-La Roche Ltd Overall survival was twice as long for people treated with Columvi in combination with…